COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics (NASDAQ:SPNC) announced the 12-month follow-up data from the CELLO study at the Leipzig Interventional Course (LINC) meeting held last week in Leipzig, Germany. The data was presented by Dr. Rajesh Dave, principal investigator of the CELLO trial and chairman, Endovascular Medicine, Pinnacle Health Heart and Vascular Institute at Harrisburg Hospital in Harrisburg, Pennsylvania.
